-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, 2019 coronavirus disease (COVID-19) continued to erupt worldwide.
but the clinical symptoms and prognosis of COVID-19 patients are not clear.
divided 843 COVID-19 patients admitted between 22 January and 14 February 2020 into three groups, depending on the onset of the initial clinical symptoms: Group A (21 January to 25 January, n - 324), and Group B (26 January to 26 January).
31 January, n , 358) and Group C (1 February to 10 February, n , 161).
collect data on demographics, symptoms, first laboratory test results, treatment and results (within 12 days of hospitalization).
results showed that the median duration from onset of symptoms to hospitalization decreased over time (13 days, 10 days and 5 days, p.lt;0.05, respectively).
group C had fewer fever symptoms and bilateral pneumonia than in Group A and Group B.
laboratory results showed lower levels of white blood cells, neutrophils and platelets, lactic acid and D-dipolymers, and higher counts in lymphocytes, CD3 and CD8 C groups.
in addition, there were fewer mild-moderate and severe cases in Group C than in the other two groups.
importantly, the incidence of complications (18.5 per cent, 14.2 per cent and 11.2 per cent, respectively, p.lt;0.05) and all-cause mortality (11.7 per cent, 8.4 per cent and 5.6 per cent, respectively) decreased over time.
the clinical characteristics and prognostication over time in patients with COVID-19.
improved at a later stage of discovery.
.